MELISSA ROWLAND: Open Payments
NPI 1558726034 · DONIPHAN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 26 payments from 15 companies in 2025. Trend: 2023 $28 · 2024 $105 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| Viatris Specialty LLC | 3 | $55 |
| Grifols USA, LLC | 3 | $52 |
| PFIZER INC. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Exact Sciences Corporation | 2 | $35 |
| Novo Nordisk Inc | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: YUPELRI, Prolastin-C Liquid, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, AIRSUPRA, GVOKE HYPOPEN, Wegovy.
Industry payments across MO — which companies pay providers there.
